Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

CD52 is expressed on malignant cells in lymphoplasmacytic lymphoma (LPL), including IgM-secreting Waldenström macroglobulinemia (WM). We examined the activity of alemtuzumab in 28 symptomatic LPL (27 IgM and 1 IgA) patients. The median prior number of therapies for these patients was 2 (range, 0-5)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Treon, Steven P., Soumerai, Jacob D., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Kahl, Brad, Boxer, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2011
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3138682/
https://ncbi.nlm.nih.gov/pubmed/21566092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-338558
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares